	US 12,435,378 B2
	*PKS-island positive E. coli* as marker of negative response to anti-PD1 therapy in colorectal cancer**
Elisabeth Billard, Clermont Ferrand (FR); Mathilde Bonnet, Vic le Comte (FR); Bruno Dumas, Paris (FR); and Amélie Lopes, Paris (FR)
Assigned to SANIFI, Paris (FR); and UNIVERSITÉ CLERMONT AUVERGNE
Appl. No. 17/299,428
Filed by SANOFI, Paris (FR); and UNIVERSITÉ CLERMONT AUVERGNE, Clermont Ferrand (FR)
PCT Filed Dec. 10, 2019, PCT No. PCT/EP2019/084487 § 371(c)(1), (2) Date Jun. 3, 2021, PCT Pub. No. WO2020/120501, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 18306661 (EP), filed on Dec. 11, 2018.
Prior Publication US 2022/0049314 A1, Feb. 17, 2022
Int. Cl. C12Q 1/6886 (2018.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C12Q 2600/106 (2013.01)]

13 Claims

1. A method for treating a subject suffering from colorectal cancer, said method comprising

i) determining the presence or absence of an E. coli pks island in a feces or colonic biopsy sample from said subject; and

ii) administering to said subject a therapeutically effective amount of an anti-cancer therapy,

wherein:

the anti-cancer therapy administered to said subject is not an anti-PD1 therapy when a pks island has been determined to be present in feces or a colonic biopsy sample from said subject, or

the anti-cancer therapy administered to said subject is an anti-PD1 antibody and/or anti-PDL1 antibody when a pks island has been determined to be absent in feces or a colonic biopsy sample from said subject.